Download 89 Kb Doc file

Supplement to Lotrionte et al – Review and Meta-analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity
Key excluded studies
First author
Year
Reason for exclusion
Bowles
2011
Lack of multivariable analysis for outcome predictors
Bu'Lock
1995
Lack of multivariable analysis for outcome predictors
Buzdar
1985
Lack of multivariable analysis for outcome predictors
Doyle
2005
Duplicate publication
Ewer
2005
Less than 200 patients included
Fumoleau
2006
Lack of multivariable analysis for outcome predictors
Goorin
1981
Lack of multivariable analysis for outcome predictors
Langer
2004
Lack of multivariable analysis for outcome predictors
Lipshultz
1991
Less than 200 patients included
Longhi
2007
Lack of multivariable analysis for outcome predictors
Mitani
2003
Lack of multivariable analysis for outcome predictors
Morgan
1981
Lack of multivariable analysis for outcome predictors
Oztarhan
2011
Lack of multivariable analysis for outcome predictors
Praga
1979
Lack of multivariable analysis for outcome predictors
Ryberg
1998
Lack of multivariable analysis for outcome predictors
Sukel
2008
Lack of multivariable analysis for outcome predictors
Testore
2008
Lack of multivariable analysis for outcome predictors
Von Hoff
1977
Lack of multivariable analysis for outcome predictors
Watts
2011
Lack of multivariable analysis for outcome predictors
1
Independent predictors cardiotoxicity*
First author
Aleman
Andolina
Age
Comorbidity
score
Cumulative dose

NS
Du
Hershman
Hudson
Krischer
↓


NS



0
NS

NS
NS
↓
NS

NS
NS



0


NS


NS
NS
NS
NS
↓
NS


Body weight
NS

↓



NS

NS
Tan-Chiu

Median odds ratio (1st3rd quartile)
NS
NS

Von Hoff
Chest
radiotherapy


Swain
Visscher
Male gender
NS

Sallan
van der Pal


NS
Ryberg
Hypertension
NS



Steinherz


Myrehaug
Schellong
AA ethnicity

NS
Brouwer
Dranitsaris
Diabetes



NS
0
NS

↓
NS



↓
NS
2.3 (1.8-2.6)
1.3 (0.9-1.7)

3.0 (2.2-4.7)
NS
1.8 (1.5-2.1)
1.3 (0.8-1.6)
↓


NS
NS
NS
1.2 (0.9-1.4)
1.4 (0.9-1.8)
3.1 (2.4-3.7)
3.5 (2.8-4.3)
*blank cells represent missing data; other predictors (anthracycline type, cancer type, dose intensity, genetic single-nucleotide polymorphisms, history of cancer relapse,
history of stem cell transplantation, left ventricular ejection fraction at baseline, trantuzumab therapy, trisomy 21) were analyzed and reported only occasionally (≤3
times) in the included studies; NS=not significant
2
Complete study references
Aleman BM, van den Belt-Dusebout AW, De Bruin ML, van 't Veer MB, Baaijens MH, de Boer JP, Hart AA, Klokman WJ, Kuenen MA, Ouwens GM, Bartelink H, van
Leeuwen FE. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109:1878-86.
Andolina JR, Dilley K. Anthracycline-induced cardiac toxicity more likely in underweight childhood cancer survivors. J Pediatr Hematol Oncol 2010;32:411-5.
Bowles EA, Wellman R, Delate T, Allen L, Feigelson HS, Yood MU, Davis R, Nekhlyudov L, McCarty C, Habel L. Magid D, Onitilo A, Freedman A, Wagner E. Cardiotoxic
chemotherapy is associated with increased heart failure risk among women with breast cancer in the cancer research network. Clin Med Res 2011;9:3-4.
Brouwer CA, Postma A, Vonk JM, Zwart N, van den Berg MP, Bink-Boelkens MT, Dolsma WV, Smit AJ, de Vries EG, Tissing WJ, Gietema JA. Systolic and diastolic
dysfunction in long-term adult survivors of childhood cancer. Eur J Cancer 2011;47:2453-62.
Bu'Lock FA, Mott MG, Oakhill A, Martin RP. Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and
pathophysiology. Br Heart J 1995;73:340-50.
Buzdar AU, Marcus C, Smith TL, Blumenschein GR. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 1985;55:2761-5.
Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol
2005;23:8597-605.
Dranitsaris G, Rayson D, Vincent M, Chang J, Gelmon K, Sandor D, Reardon G. The development of a predictive model to estimate cardiotoxic risk for patients with
metastatic breast cancer receiving anthracyclines. Breast Cancer Res Treat 2008;107:443-50.
Du XL, Xia R, Liu CC, Cormier JN, Xing Y, Hardy D, Chan W, Burau K. Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast
cancer. Cancer 2009;115:5296-308.
Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005;23:2900-2.
Fumoleau P, Roché H, Kerbrat P, Bonneterre J, Romestaing P, Fargeot P, Namer M, Monnier A, Montcuquet P, Goudier MJ, Luporsi E; French Adjuvant Study Group.
Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol 2006;17:85-92.
Goorin AM, Borow KM, Goldman A, Williams RG, Henderson IC, Sallan SE, Cohen H, Jaffe N. Congestive heart failure due to adriamycin cardiotoxicity: its natural history
in children. Cancer 1981;47:2810-6.
3
Hershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell
non-Hodgkin's lymphoma. J Clin Oncol 2008;26:3159-65.
Hudson MM, Rai SN, Nunez C, Merchant TE, Marina NM, Zalamea N, Cox C, Phipps S, Pompeu R, Rosenthal D. Noninvasive evaluation of late anthracycline cardiac
toxicity in childhood cancer survivors. J Clin Oncol 2007;25:3635-43.
Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric
Oncology Group experience. J Clin Oncol 1997;15:1544-52.
Langer T, Stöhr W, Bielack S, Paulussen M, Treuner J, Beck JD; German Late Effects Working Group in the German Society of Pediatric Oncology and Hematology. Late
effects surveillance system for sarcoma patients. Pediatr Blood Cancer 2004;42:373-9.
Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.
N Engl J Med 1991;324:808-15.
Longhi A, Ferrari S, Bacci G, Specchia S. Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma. Anticancer
Drugs. 2007;18:737-44.
Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium
radionuclide angiocardiography in the current era. J Nucl Cardiol 2003;10:132-9.
Morgan GW, McIlveen BM, Freedman A, Murray IP. Radionuclide ejection fraction in doxorubicin cardiotoxicity. Cancer Treat Rep 1981;65:629-38.
Myrehaug S, Pintilie M, Tsang R, Mackenzie R, Crump M, Chen Z, Sun A, Hodgson DC. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supraadditive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 2008;49:1486-93.
Oztarhan K, Guler S, Aktas B, Arslan M, Salcioglu Z, Aydogan G. The value of echocardiography versus cardiac troponin I levels in the early detection of anthracycline
cardiotoxicity in childhood acute leukemia: prospective evaluation of a 7-year-long clinical follow-up. Pediatr Hematol Oncol 2011;28:380-94.
Praga C, Beretta G, Vigo PL, Lenaz GR, Pollini C, Bonadonna G, Canetta R, Castellani R, Villa E, Gallagher CG, von Melchner H, Hayat M, Ribaud P, De Wasch G,
Mattsson W, Heinz R, Waldner R, Kolaric K, Buehner R, Ten Bokkel-Huyninck W, Perevodchikova NI, Manziuk LA, Senn HJ, Mayr AC. Adriamycin cardiotoxicity: a
survey of 1273 patients. Cancer Treat Rep 1979;63:827-34.
4
Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer
patients. J Natl Cancer Inst 2008;100:1058-67.
Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin
Oncol 1998;16:3502-8.
Sallan SE, Clavell LA. Cardiac effects of anthracyclines used in the treatment of childhood acute lymphoblastic leukemia: a 10-year experience. Semin Oncol 1984;11:1921.
Schellong G, Riepenhausen M, Bruch C, Kotthoff S, Vogt J, Bölling T, Dieckmann K, Pötter R, Heinecke A, Brämswig J, Dörffel W. Late valvular and other cardiac
diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the
German-Austrian DAL-HD studies. Pediatr Blood Cancer 2010;55:1145-52.
Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672-7.
Sukel MP, Breekveldt-Postma NS, Erkens JA, van der Linden PD, Beiderbeck AB, Coebergh JW, Herings RM. Incidence of cardiovascular events in breast cancer patients
receiving chemotherapy in clinical practice. Pharmacoepidemiol Drug Saf 2008;17:125-34.
Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869-79.
Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP,
Wolmark N, Bryant J. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without
trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-9.
Testore F, Milanese S, Ceste M, de Conciliis E, Parello G, Lanfranco C, Manfredi R, Ferrero G, Simoni C, Miglietta L, Ferro S, Giaretto L, Bosso G. Cardioprotective effect
of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience. Am J Cardiovasc Drugs
2008;8:257-63.
van der Pal HJ, van Dalen EC, Hauptmann M, Kok WE, Caron HN, van den Bos C, Oldenburger F, Koning CC, van Leeuwen FE, Kremer LC. Cardiac function in 5-year
survivors of childhood cancer: a long-term follow-up study. Arch Intern Med 2010;170:1247-55.
5
Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dubé MP, Al-Saloos H, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Brown AM, Rogers PC, Phillips
MS, Rieder MJ, Carleton BC, Hayden MR; Canadian Pharmacogenomics Network for Drug Safety Consortium. Pharmacogenomic Prediction of Anthracycline-Induced
Cardiotoxicity in Children. J Clin Oncol 2012;30:1422-8.
Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med
1979;91:710-7.
Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 1977;62:200-8.
Watts RG, George M, Johnson WH Jr. Pretreatment and routine echocardiogram monitoring during chemotherapy for anthracycline-induced cardiotoxicity rarely identifies
significant cardiac dysfunction or alters treatment decisions: A 5-Year Review at a Single Pediatric Oncology Center. Cancer 2011 Cancer 2012;118:1919-24.
6